Abstract：
UNASSIGNED: This real-world retrospective database study quantified the costs of biomarker testing in a US population of patients with lung or thyroid cancers.
UNASSIGNED: The commercial claims IBM Marketscan database, a de-identified real-world dataset, was used to identify patients diagnosed with lung or thyroid cancer between 1/2015 and 12/2019. Eligible patients were 18 years or older with two or more lung or thyroid diagnosis codes. Patients were excluded who had evidence of prior cancer diagnoses. Subgroup analyses evaluated eligible patients with metastatic disease. Descriptive statistics were used to evaluate commercial insurance plan payer and patient out-of-pocket costs for diagnostic testing overall as well as by test procedure code and payer type. Costs were adjusted to 2020 US dollars.
UNASSIGNED: A total of 23,633 patients with lung cancer were eligible, 13,320 of whom had metastatic disease. There were 36,867 patients with thyroid cancer, 2,241 of whom had metastatic disease. Biomarker codes were observed among 68.4/75.8% (lung/metastatic lung) and 18.2/42.3% (thyroid/metastatic thyroid). Few patients had codes for comprehensive biomarker tests (5.2/6.7% lung/metastatic lung, 0.3/2.2% thyroid/metastatic thyroid) Among those with biomarker tests, the median per-patient total payer lifetime costs of all biomarker testing were $394/$462 (lung/metastatic lung) and $148/$232 (thyroid/metastatic thyroid). Total lifetime biomarker costs for payers ranged from a median of $128 (consumer-driven health plans) to $477 (preferred provider organizations). Median lifetime patient out-of-pocket costs were $0.00 for both tumor types and all payer types except for consumer-driven health plans ($12 for thyroid and $10 for metastatic lung).
UNASSIGNED: While comprehensive testing adds to the cost of biomarker testing, these data suggest the relatively low lifetime cost of biomarker testing for both payers and patients. Costs for biomarker testing should not be a limitation to access among these populations with commercial insurance plans in the US.
This real-world retrospective database study found that there is a relatively low lifetime total cost of biomarker testing for the care of patients with lung or thyroid cancers. While comprehensive testing adds to the cost of biomarker testing, these data suggest the relatively low lifetime cost of biomarker testing for both payers and patients. Payer costs for biomarker testing do not appear to be limitation to access among populations with commercial insurance plans in this study.
UNASSIGNED: The commercial claims IBM Marketscan database, a de-identified real-world dataset, was used to identify patients diagnosed with lung or thyroid cancer between 1/2015 and 12/2019. Eligible patients were 18 years or older with two or more lung or thyroid diagnosis codes. Patients were excluded who had evidence of prior cancer diagnoses. Subgroup analyses evaluated eligible patients with metastatic disease. Descriptive statistics were used to evaluate commercial insurance plan payer and patient out-of-pocket costs for diagnostic testing overall as well as by test procedure code and payer type. Costs were adjusted to 2020 US dollars.
UNASSIGNED: A total of 23,633 patients with lung cancer were eligible, 13,320 of whom had metastatic disease. There were 36,867 patients with thyroid cancer, 2,241 of whom had metastatic disease. Biomarker codes were observed among 68.4/75.8% (lung/metastatic lung) and 18.2/42.3% (thyroid/metastatic thyroid). Few patients had codes for comprehensive biomarker tests (5.2/6.7% lung/metastatic lung, 0.3/2.2% thyroid/metastatic thyroid) Among those with biomarker tests, the median per-patient total payer lifetime costs of all biomarker testing were $394/$462 (lung/metastatic lung) and $148/$232 (thyroid/metastatic thyroid). Total lifetime biomarker costs for payers ranged from a median of $128 (consumer-driven health plans) to $477 (preferred provider organizations). Median lifetime patient out-of-pocket costs were $0.00 for both tumor types and all payer types except for consumer-driven health plans ($12 for thyroid and $10 for metastatic lung).
UNASSIGNED: While comprehensive testing adds to the cost of biomarker testing, these data suggest the relatively low lifetime cost of biomarker testing for both payers and patients. Costs for biomarker testing should not be a limitation to access among these populations with commercial insurance plans in the US.
This real-world retrospective database study found that there is a relatively low lifetime total cost of biomarker testing for the care of patients with lung or thyroid cancers. While comprehensive testing adds to the cost of biomarker testing, these data suggest the relatively low lifetime cost of biomarker testing for both payers and patients. Payer costs for biomarker testing do not appear to be limitation to access among populations with commercial insurance plans in this study.
摘要：
UNASSIGNED：这项真实世界的回顾性数据库研究量化了美国肺癌或甲状腺癌患者中生物标志物检测的成本。
UNASSIGNED：商业声称IBMMarketscan数据库，一个去识别的现实世界数据集，用于识别2015年1月至2019年12月之间诊断为肺癌或甲状腺癌的患者。符合条件的患者为18岁或以上，具有两个或更多个肺或甲状腺诊断代码。排除具有先前癌症诊断证据的患者。亚组分析评估了合格的转移性疾病患者。描述性统计数据用于评估商业保险计划付款人和患者自付费用，以进行总体诊断测试以及测试程序代码和付款人类型。成本调整为2020美元。
UNASSIGNED：共有23,633名肺癌患者符合条件，其中13,320人患有转移性疾病。有36,867名甲状腺癌患者，其中2,241人患有转移性疾病。在68.4%/75.8%(肺/转移性肺)和18.2%/42.3%(甲状腺/转移性甲状腺)中观察到生物标志物代码。很少有患者具有综合生物标志物测试的代码（5.2％/6.7％肺/转移性肺，0.3%/2.2%甲状腺/转移性甲状腺)在进行生物标志物检测的人群中，所有生物标志物检测的每位患者的总费用中位数分别为$394/$462(肺/转移性肺)和$148/$232(甲状腺/转移性甲状腺).付款人的终生生物标志物总费用从128美元（消费者驱动的健康计划）到477美元（首选提供者组织）不等。除消费者驱动的健康计划外，肿瘤类型和所有付款人类型的患者终生自付费用中位数为0.00美元（甲状腺12美元，转移性肺10美元）。
未经评估：虽然全面测试增加了生物标志物测试的成本，这些数据表明,对于支付者和患者而言,生物标志物检测的终生成本相对较低.在美国，生物标志物测试的成本不应限制这些人群获得商业保险计划。
UNASSIGNED：商业声称IBMMarketscan数据库，一个去识别的现实世界数据集，用于识别2015年1月至2019年12月之间诊断为肺癌或甲状腺癌的患者。符合条件的患者为18岁或以上，具有两个或更多个肺或甲状腺诊断代码。排除具有先前癌症诊断证据的患者。亚组分析评估了合格的转移性疾病患者。描述性统计数据用于评估商业保险计划付款人和患者自付费用，以进行总体诊断测试以及测试程序代码和付款人类型。成本调整为2020美元。
UNASSIGNED：共有23,633名肺癌患者符合条件，其中13,320人患有转移性疾病。有36,867名甲状腺癌患者，其中2,241人患有转移性疾病。在68.4%/75.8%(肺/转移性肺)和18.2%/42.3%(甲状腺/转移性甲状腺)中观察到生物标志物代码。很少有患者具有综合生物标志物测试的代码（5.2％/6.7％肺/转移性肺，0.3%/2.2%甲状腺/转移性甲状腺)在进行生物标志物检测的人群中，所有生物标志物检测的每位患者的总费用中位数分别为$394/$462(肺/转移性肺)和$148/$232(甲状腺/转移性甲状腺).付款人的终生生物标志物总费用从128美元（消费者驱动的健康计划）到477美元（首选提供者组织）不等。除消费者驱动的健康计划外，肿瘤类型和所有付款人类型的患者终生自付费用中位数为0.00美元（甲状腺12美元，转移性肺10美元）。
未经评估：虽然全面测试增加了生物标志物测试的成本，这些数据表明,对于支付者和患者而言,生物标志物检测的终生成本相对较低.在美国，生物标志物测试的成本不应限制这些人群获得商业保险计划。
